Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.00 price target on the stock.
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $8.00 price target on the stock, up previously from $2.00.